← Back to Search
HIV Dynamics And T-cell Immunity After Three Structured Treatment Interruptions In Chronic HIV-1 Infection
L. Ruiz, G. Carcelain, J. Martinez-Picado, S. Frost, S. Marfil, R. Paredes, J. Romeu, E. Ferrer, K. Morales-Lopetegi, B. Autran, B. Clotet
Published 2001 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
ObjectiveTo evaluate whether controlled re-exposures to autologous HIV-1 could boost HIV-specific immunity and limit virus replication in patients with chronic HIV-1 infection. Patients and designSubjects with at least 2 years virus suppression during antiretroviral therapy and a CD4 : CD8 ratio > 1 were randomly assigned to interrupt highly active antiretroviral treatment (HAART) three times (n = 12) or to continue their previous HAART (n = 14). ResultsIn 10/12 interrupter patients a rebound of HIV-1 RNA was detected in all three structured treatment interruptions (STI). Plasma virus doubling time was shorter during the first STI than in the second and third STI, corresponding to an average 13% reduction in viral basic reproductive rate. However, the mean time before plasma viral load rose to > 50 copies/ml was significantly shorter in the second and third STI. The average frequency of HIV-specific CD8 T cells in the interrupter patients at the end of the third STI cycle was significantly higher compared with the baseline and the end of the first STI. A substantial increase in HIV-specific CD8 T cell frequencies was found in four interrupter patients, whereas there were no changes in all 14 non-interrupter individuals. A weak p24-specific T helper response developed in 5/12 interrupter patients compared with no response in non-interruptors, but these responses were transient and disappeared rapidly. ConclusionThe increase in the control of viral replication, and positive effects of STI on immune responses in this population should encourage the further development of HIV-specific immune-based therapeutic strategies.
This paper references
Molecular determinants of macrophage tropism and viral persistence: importance of single amino acid changes in the polymerase and glycoprotein of lymphocytic choriomeningitis virus
M. Matloubian (1993)
CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
M. Matloubian (1994)
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
D. Ho (1995)
Viral dynamics in human immunodeficiency virus type 1 infection
X. Wei (1995)
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
B. Autran (1997)
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.
E. Rosenberg (1997)
Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.
M. Dalod (1998)
Impact on the immune system of undetectable plasma HIV‐1 RNA for more than 2 years
A. Arnó (1998)
Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
T. Li (1998)
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease
M. Plana (1998)
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
M. Lederman (1998)
Long-lasting recovery in CD4 T-cell function and viral-load AIDS 2001, Vol 15 No 9 F26 reduction after highly active antiretroviral therapy in advanced HIV-1 disease
TS Li (1998)
Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
C. Rinaldo (1999)
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
A. Neumann (1999)
Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy.
O. Pontesilli (1999)
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
F. García (1999)
HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
C. Pitcher (1999)
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
A. Carr (1999)
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.
R. Davey (1999)
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
L. Zhang (1999)
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
D. Finzi (1999)
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.
G. Ortiz (1999)
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
M. Furtado (1999)
Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy
G. Ogg (1999)
Control of HIV despite the discontinuation of antiretroviral therapy.
J. Lisziewicz (1999)
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).
C. Gray (1999)
HIV-1-speci®c immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy
GM Ortiz (1999)
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
L. Ruiz (2000)
Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy.
P. Haslett (2000)
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes.
A. Oxenius (2000)
Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption.
E. Papasavvas (2000)
Dynamics of HIV-Specific CD8+ T Lymphocytes with Changes in Viral Load1
L. Mollet (2000)
Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups.
L. Mollet (2000)
Antiretroviral resistance during successful therapy of HIV type 1 infection.
J. Martinez-Picado (2000)
Immune control of HIV-1 after early treatment of acute infection
E. Rosenberg (2000)
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
B. Ramratnam (2000)
WinBUGS version 1.2 user manual
DJ Spiegelhalter (2000)
Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection
Guislaine Carcelain (2001)
This paper is referenced by
Clinical trials of antiretroviral treatment interruption in HIV-infected individuals
J. Lau (2019)
Global dynamics and cost-effectiveness analysis of HIV pre-exposure prophylaxis and structured treatment interruptions based on a multi-scale model
M. Shen (2019)
Systematic Review And Meta-Analysis of Treatment Interruptions in HIV-1 Infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials.
M. Stecher (2019)
Positive Feedback Through Inflammation Creates Bistable Behavior in HIV Tissue Sanctuaries
Aditya Jagarapu (2019)
Insight into treatment of HIV infection from viral dynamics models
A. Hill (2018)
Integration of Reaction Kinetics Theory and Gene Expression Programming to Infer Reaction Mechanism
Jason R. White (2017)
HIV models for treatment interruption: Adaptation and comparison
Andreas Hillmann (2017)
Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
M. Pinkevych (2016)
Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions
A. Hill (2016)
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
M. Pinkevych (2015)
Recomendations from GESIDA/National AIDS plan on antiretroviral therapy in adult patients infected by the human immunodeficiency virus (October 2004)
J. Iribarren (2015)
Analysis of HIV-1 compartmental model parameters using Bayesian MCMC estimation
E. F. Cardozo (2014)
MESSA A PUNTO DI TEST ALTERNATIVI PER LO SCREENING DI POTENZIALI INIBITORI DELLA PROTEASI DI HIV-1
D. Parolin (2014)
Immune interventions in HIV infection
G. Carcelain (2013)
Association of early HIV viremia with mortality after HIV-associated lymphoma
S. Gopal (2013)
HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics
Rutao Luo (2012)
An “Escape Clock” for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells
J. Reece (2012)
HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation
G. Goldstein (2012)
Robust Closed-Loop Minimal Sampling Method for HIV Therapy Switching Strategies
E. F. Cardozo (2012)
Structured Treatment Interruption in Patients Infected with HIV
R. Gulick (2012)
Estudi de l’evolució de l’envolta del VIH-1 en pacients infectats sotmesos a vacunació terapèutica amb virus autòleg inactivat
Meritxell Guilà Matarin (2011)
Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching
E. F. Cardozo (2011)
Approximate-model closed-loop minimal sampling method for HIV viral-load minima detection
R. Zurakowski (2011)
Controlling the Evolution of Resistance.
Rutao Luo (2011)
[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy
Rutao Luo (2011)
Human immunodeficiency virus type 1 genetic diversity in the nervous system: Evolutionary epiphenomenon or disease determinant?
G. Marle (2011)
The Gut Mucosal Viral Reservoir in HIV-Infected Patients Is Not the Major Source of Rebound Plasma Viremia following Interruption of Highly Active Antiretroviral Therapy
Paula Lerner (2011)
Nonlinear observer output-feedback MPC treatment scheduling for HIV
R. Zurakowski (2011)
Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical data
Rutao Luo (2011)
Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching
Rutao Luo (2010)
Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease
D. Jochmans (2010)See more